Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
作者信息
Olujohungbe A, Cinkotai K I, Yardumian A
出版信息
BMJ. 1998 Jun 6;316(7146):1689. doi: 10.1136/bmj.316.7146.1689.
Abstract
摘要
相似文献
1
Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.英国镰状细胞病的羟基脲疗法。尽管结果令人鼓舞，但招募情况令人失望。
BMJ. 1998 Jun 6;316(7146):1689. doi: 10.1136/bmj.316.7146.1689.
2
Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.非洲镰状细胞贫血的羟基脲治疗：注意差距。
Lancet Glob Health. 2015 Mar;3(3):e124-5. doi: 10.1016/S2214-109X(14)70371-7.
3
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.羟基脲对镰状细胞贫血的幼儿并非万灵药。
J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093.
4
Hydroxyurea for sickle cell anemia.羟基脲用于镰状细胞贫血。
N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9.
5
Hydroxurea and sickle cell disease: Its been a long, long time coming.羟基脲与镰状细胞病：这一天姗姗来迟。
Pediatr Blood Cancer. 2010 Feb;54(2):185-6. doi: 10.1002/pbc.22340.
6
Hydroxyurea for the treatment of sickle cell anemia.羟基脲用于治疗镰状细胞贫血。
N Engl J Med. 2008 Mar 27;358(13):1362-9. doi: 10.1056/NEJMct0708272.
7
Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.在马拉维的卡穆祖中央医院，镰状细胞病患儿使用羟基脲的情况日益增多。
Blood Adv. 2018 Nov 30;2(Suppl 1):30-32. doi: 10.1182/bloodadvances.2018GS110347.
8
Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease.羟基脲对青春期前镰状细胞病患者的精原细胞库没有影响。
Blood. 2021 Feb 11;137(6):856-859. doi: 10.1182/blood.2020008146.
9
[Edifying affair of hydroxycarbamid].[羟基脲的启迪之事]
Rev Med Suisse. 2008 Apr 9;4(152):940.
10
Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia.一名接受羟基脲治疗的镰状细胞贫血患者发生的治疗相关急性髓性白血病。
Ann Intern Med. 2011 Nov 15;155(10):722-4. doi: 10.7326/0003-4819-155-10-201111150-00024.
引用本文的文献
1
Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.羟基脲治疗镰状细胞贫血患者的氧化应激评估。
Ann Hematol. 2020 May;99(5):937-945. doi: 10.1007/s00277-020-03987-7. Epub 2020 Mar 12.
2
Experiences of hospital care and treatment-seeking behavior for pain from sickle cell disease: qualitative study.镰状细胞病疼痛的住院护理及就医行为体验：定性研究
West J Med. 1999 Nov;171(5-6):306-13.
3
Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.镰状细胞病疼痛的住院护理及寻求治疗经历：定性研究
BMJ. 1999 Jun 12;318(7198):1585-90. doi: 10.1136/bmj.318.7198.1585.
4
Register cannot replace prospective studies in sickle cell disease.登记不能替代镰状细胞病的前瞻性研究。
BMJ. 1999 Mar 6;318(7184):671. doi: 10.1136/bmj.318.7184.671a.
5
European register of patients with sickle cell disease treated with hydroxyurea is being set up.欧洲正在建立接受羟基脲治疗的镰状细胞病患者登记册。
BMJ. 1998 Aug 22;317(7157):541-2. doi: 10.1136/bmj.317.7157.541a.
本文引用的文献
1
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.羟基脲治疗重度镰状细胞贫血：一项儿科临床试验。
Blood. 1996 Sep 15;88(6):1960-4.
2
Novel treatment options in the severe beta-globin disorders.重度β-珠蛋白生成障碍性贫血的新型治疗选择。
Br J Haematol. 1995 Oct;91(2):263-8. doi: 10.1111/j.1365-2141.1995.tb05288.x.
3
Mortality in sickle cell disease. Life expectancy and risk factors for early death.镰状细胞病的死亡率。预期寿命和早期死亡的风险因素。
N Engl J Med. 1994 Jun 9;330(23):1639-44. doi: 10.1056/NEJM199406093302303.
4
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.羟基脲对镰状细胞贫血疼痛性危象发作频率的影响。镰状细胞贫血羟基脲多中心研究的研究者们。
N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001.
5
6
Sickle cell disease in North London.伦敦北部的镰状细胞病。
Br J Haematol. 1987 Aug;66(4):543-7. doi: 10.1111/j.1365-2141.1987.tb01342.x.
7
Pain in sickle cell disease. Rates and risk factors.镰状细胞病中的疼痛。发生率及危险因素。
N Engl J Med. 1991 Jul 4;325(1):11-6. doi: 10.1056/NEJM199107043250103.
8
Comparison of homozygous sickle cell disease in northern Greece and Jamaica.希腊北部和牙买加纯合子镰状细胞病的比较。
Lancet. 1990 Mar 17;335(8690):637-40. doi: 10.1016/0140-6736(90)90419-6.
Zotero 插件